76 related articles for article (PubMed ID: 24225331)
1. High-risk multiple myeloma: different definitions, different outcomes?
Paszekova H; Kryukov F; Kubiczkova L; Hajek R; Sevcikova S
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):24-30. PubMed ID: 24225331
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities.
Zhou P; Li W; Zuo S; Ma R; Yuan X; Zhu Z
Leuk Lymphoma; 2023; 64(8):1373-1388. PubMed ID: 37300424
[TBL] [Abstract][Full Text] [Related]
3. A rational approach to functional high-risk myeloma.
Gay F; Bertuglia G; Mina R
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):433-442. PubMed ID: 38066896
[TBL] [Abstract][Full Text] [Related]
4. Approach to High-Risk Multiple Myeloma.
Chen X; Varma G; Davies F; Morgan G
Hematol Oncol Clin North Am; 2024 Apr; 38(2):497-510. PubMed ID: 38195306
[TBL] [Abstract][Full Text] [Related]
5. High-risk multiple myeloma: Redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy.
Rees MJ; Kumar S
Am J Hematol; 2024 Apr; ():. PubMed ID: 38613829
[TBL] [Abstract][Full Text] [Related]
6. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.
Vincent Rajkumar S
Am J Hematol; 2014 Oct; 89(10):999-1009. PubMed ID: 25223428
[TBL] [Abstract][Full Text] [Related]
7. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
Rajkumar SV; Dimopoulos MA; Palumbo A; Blade J; Merlini G; Mateos MV; Kumar S; Hillengass J; Kastritis E; Richardson P; Landgren O; Paiva B; Dispenzieri A; Weiss B; LeLeu X; Zweegman S; Lonial S; Rosinol L; Zamagni E; Jagannath S; Sezer O; Kristinsson SY; Caers J; Usmani SZ; Lahuerta JJ; Johnsen HE; Beksac M; Cavo M; Goldschmidt H; Terpos E; Kyle RA; Anderson KC; Durie BG; Miguel JF
Lancet Oncol; 2014 Nov; 15(12):e538-48. PubMed ID: 25439696
[TBL] [Abstract][Full Text] [Related]
8. Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice.
Landgren O; Morgan GJ
Clin Cancer Res; 2014 Feb; 20(4):804-13. PubMed ID: 24270684
[TBL] [Abstract][Full Text] [Related]
9. Antigen Expression Patterns of Plasma Cell Myeloma: An Association of Cytogenetic Abnormality and International Staging System (ISS) for Myeloma.
Shin SY; Lee ST; Kim HJ; Kim SJ; Kim K; Kang ES; Kim SH
J Clin Lab Anal; 2015 Nov; 29(6):505-10. PubMed ID: 25277787
[TBL] [Abstract][Full Text] [Related]
10. Myeloma genetics and genomics: practice implications and future directions.
Faiman B
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):436-40. PubMed ID: 25127058
[TBL] [Abstract][Full Text] [Related]
11. Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma.
Bianchi G; Ghobrial IM
Curr Cancer Ther Rev; 2014; 10(2):70-79. PubMed ID: 25705146
[TBL] [Abstract][Full Text] [Related]
12. Multiple myeloma: a model for scientific and clinical progress.
San Miguel J
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):1-7. PubMed ID: 25696828
[TBL] [Abstract][Full Text] [Related]
13. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.
Hebraud B; Magrangeas F; Cleynen A; Lauwers-Cances V; Chretien ML; Hulin C; Leleu X; Yon E; Marit G; Karlin L; Roussel M; Stoppa AM; Belhadj K; Voillat L; Garderet L; Macro M; Caillot D; Mohty M; Facon T; Moreau P; Attal M; Munshi N; Corre J; Minvielle S; Avet-Loiseau H
Blood; 2015 Mar; 125(13):2095-100. PubMed ID: 25636340
[TBL] [Abstract][Full Text] [Related]
14. Risk stratification in multiple myeloma, part 1: characterization of high-risk disease.
Biran N; Jagannath S; Chari A
Clin Adv Hematol Oncol; 2013 Aug; 11(8):489-503. PubMed ID: 24518420
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.
Bolli N; Avet-Loiseau H; Wedge DC; Van Loo P; Alexandrov LB; Martincorena I; Dawson KJ; Iorio F; Nik-Zainal S; Bignell GR; Hinton JW; Li Y; Tubio JM; McLaren S; O' Meara S; Butler AP; Teague JW; Mudie L; Anderson E; Rashid N; Tai YT; Shammas MA; Sperling AS; Fulciniti M; Richardson PG; Parmigiani G; Magrangeas F; Minvielle S; Moreau P; Attal M; Facon T; Futreal PA; Anderson KC; Campbell PJ; Munshi NC
Nat Commun; 2014; 5():2997. PubMed ID: 24429703
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetic classification in Korean multiple myeloma patients: prognostic significance of hyperdiploidy with 47-50 chromosomes and the number of structural abnormalities.
Lim JH; Seo EJ; Park CJ; Jang S; Chi HS; Suh C; Kim H; Kim SR
Eur J Haematol; 2014 Apr; 92(4):313-20. PubMed ID: 24372944
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.
Abdi J; Chen G; Chang H
Oncotarget; 2013 Dec; 4(12):2186-207. PubMed ID: 24327604
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant.
Langer P; John L; Monsef I; Scheid C; Piechotta V; Skoetz N
Cochrane Database Syst Rev; 2024 May; 5(5):CD013595. PubMed ID: 38695605
[TBL] [Abstract][Full Text] [Related]
19. Predicting cytogenetic risk in multiple myeloma using conventional whole-body MRI, spinal dynamic contrast-enhanced MRI, and spinal diffusion-weighted imaging.
Van Den Berghe T; Verberckmoes B; Kint N; Wallaert S; De Vos N; Algoet C; Behaeghe M; Dutoit J; Van Roy N; Vlummens P; Dendooven A; Van Dorpe J; Offner F; Verstraete K
Insights Imaging; 2024 Apr; 15(1):106. PubMed ID: 38597979
[TBL] [Abstract][Full Text] [Related]
20. Variability of definition of high-risk multiple myeloma across phase III clinical trials.
Abu Za'nouneh FJ; Ababneh O; Schinke C; Thanendrarajan S; Zangari M; Shaughnessy JD; Zhan F; van Rhee F; Al Hadidi S
EJHaem; 2023 May; 4(2):454-458. PubMed ID: 37206288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
